Cadisegliatin TTP-399|cas:859525-02-3|西域试剂

Cadisegliatin TTP-399,99.10%

产品编号：Bellancom-147254| CAS NO：859525-02-3| 分子式：C₂₁H₃₃N₃O₄S₂| 分子量：455.63

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-147254	￥3000.00	杭州北京（现货）
Bellancom-147254	￥4800.00	杭州北京（现货）
Bellancom-147254	￥9500.00	杭州北京（现货）
Bellancom-147254	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cadisegliatin TTP-399

产品介绍

Cadisegliatin (TTP-399) 是一种潜在的肝脏选择性葡萄糖激酶 (GK) 激活剂，具有口服活性。Cadisegliatin 具有降血糖活性，Cadisegliatin 可用于 2 型糖尿病的研究。

生物活性

Cadisegliatin (TTP-399) is a potential, orally active liver-selective glucokinase (GK) activator. Cadisegliatin has antihyperglycaemic activity. Cadisegliatin can be used for the research of type 2 diabetes.

体外研究

Cadisegliatin (TTP-399) 增加大鼠肝细胞的葡萄糖代谢，15 nM 葡萄糖中乳酸和糖原的 EC₅₀ 值分别为 2.39 μM 和 2.64 μM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

TTP399（200 mg/kg，口服，口服）对禁食大鼠的血浆葡萄糖和胰岛素没有影响。
TTP399（75 或 150 mg/kg，每天，持续 4 周）改善 ob/ob 小鼠模型的葡萄糖稳态。
TTP399（50 mg/kg，每天，持续 13 周）在小型猪模型的口服葡萄糖耐量试验 (OGTT) 期间有效降低血浆葡萄糖。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nondiabetic fasted rats
Dosage:	200 mg/kg
Administration:	200 mg/kg, per os (p.o.)
Result:	Did not change the insulin and glucose concentrations in plasma.

Animal Model:	ob/ob mouse model
Dosage:	75 or 150 mg/kg
Administration:	75 or 150 mg/kg, per day, for 4 weeks
Result:	Reduced the expression of HbA1c, blood glucose concentrations, lactate concentrations and liver glycogen depots. Improved the lipid profile, reduced plasma, liver TG concentrations and the weight gain at the highest dose.

Animal Model:	Gottingen minipigs
Dosage:	50 mg/kg
Administration:	50 mg/kg, per day, for 13 weeks
Result:	Eliminated the blood glucose excursion in Minipigs.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nondiabetic fasted rats
Dosage:	200 mg/kg
Administration:	200 mg/kg, per os (p.o.)
Result:	Did not change the insulin and glucose concentrations in plasma.

Animal Model:	ob/ob mouse model
Dosage:	75 or 150 mg/kg
Administration:	75 or 150 mg/kg, per day, for 4 weeks
Result:	Reduced the expression of HbA1c, blood glucose concentrations, lactate concentrations and liver glycogen depots. Improved the lipid profile, reduced plasma, liver TG concentrations and the weight gain at the highest dose.

Animal Model:	Gottingen minipigs
Dosage:	50 mg/kg
Administration:	50 mg/kg, per day, for 13 weeks
Result:	Eliminated the blood glucose excursion in Minipigs.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (274.35 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1948 mL	10.9738 mL	21.9476 mL
5 mM	0.4390 mL	2.1948 mL	4.3895 mL
10 mM	0.2195 mL	1.0974 mL	2.1948 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献